Integrated Genomics names new president and CEO
Prior to Integrated Genomics, Mr Sheridan was vice president of commercial operations at HTG where he was responsible for forming new business partnerships with pharmaceutical and life sciences
Daiichi Sankyo and Merck & Co (MSD) have voluntarily withdrawn their biologics license application (BLA) for ifinatamab deruxtecan, aimed at treating adult patients with extensive-stage small cell lung cancer (ES-SCLC) following disease progression after platinum-based chemotherapy.
Saturn is a placebo-controlled, randomized, double-blind, Phase III study conducted by Roche that enrolled 889 patients with advanced non-small cell lung cancer (NSCLC) at approximately 160 sites worldwide.